About Merus Labs International (TSE:MSL)
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Sector: N/A
- Symbol: TSE:MSL
- CUSIP: N/A
- Web: www.meruslabs.com
- Trailing EPS: C($0.11)
- Net Margins: -5.18%
- Return on Equity: -2.51%
- Return on Assets: -1.32%
- Outstanding Shares: 117,355,000
Frequently Asked Questions for Merus Labs International (TSE:MSL)
What is Merus Labs International's stock symbol?
Merus Labs International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MSL."
Where is Merus Labs International's stock going? Where will Merus Labs International's stock price be in 2017?
5 Wall Street analysts have issued 1-year target prices for Merus Labs International's stock. Their predictions range from C$1.00 to C$3.00. On average, they anticipate Merus Labs International's share price to reach C$1.99 in the next year. View Analyst Ratings for Merus Labs International.
Who are some of Merus Labs International's key competitors?
Some companies that are related to Merus Labs International include Royal Bank of Canada (RY), Toronto-Dominion Bank (TD), Bank of Nova Scotia (BNS), Canadian National Railway Company (CNR), Suncor Energy (SU), Enbridge (ENB), Bank of Montreal (BMO), BCE (BCE), TransCanada (TRP), Canadian Natural Resources Limited (CNQ), Manulife Financial Corp. (MFC), Brookfield Asset Management (BAM.A), Canadian Imperial Bank of Commerce (CM), Thomson Reuters (TRI), Restaurant Brands International (QSR), Alimentation Couche-Tard (ATD.A), Alimentation Couche-Tard (ATD.B) and Rogers Communications (RCI.B).
Who are Merus Labs International's key executives?
Merus Labs International's management team includes the folowing people:
- Michael S. Cloutier, Independent Chairman of the Board
- Barry Fishman, Chief Executive Officer, Director
- Michael Scott Bumby, Chief Financial Officer
- Robert McLay, Vice President - Sales and Marketing
- Frank Rotmann, Vice President and Head of European Operations
- Robert Bloch M.D., Director
- Theresa Sheila Firestone, Independent Director
- David D. Guebert CPA, Independent Director
- Robert S. Pollock, Independent Director
- Timothy G. Sorensen, Independent Director
How do I buy Merus Labs International stock?
Shares of Merus Labs International and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How can I contact Merus Labs International?
Merus Labs International's mailing address is 100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151, TORONTO, ON M5K 1H1, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-7260995.
MarketBeat Community Rating for Merus Labs International (TSE MSL)MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Merus Labs International (TSE:MSL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 4 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.20)|
|Consensus Price Target: ||C$1.99|
Consensus Price Target History for Merus Labs International (TSE:MSL)
Analysts' Ratings History for Merus Labs International (TSE:MSL)
(Data available from 11/18/2015 forward)
|5/15/2017||CIBC||Boost Price Target||C$1.40 -> C$1.65|
|5/12/2017||Scotiabank||Boost Price Target||Sector Perform||C$1.25 -> C$1.65|
|5/12/2017||TD Securities||Lower Price Target||Buy -> Tender||C$3.00 -> C$1.65|
|2/13/2017||Bloom Burton||Reiterated Rating||Hold|
|12/15/2016||Paradigm Capital||Lower Price Target||Hold||C$1.60 -> C$1.00|
|12/15/2016||Canaccord Genuity||Lower Price Target||Buy||C$3.50 -> C$3.00|
|12/15/2016||Royal Bank Of Canada||Lower Price Target||C$3.50 -> C$3.00|
|2/2/2016||Cormark||Upgrade||Speculative Buy -> Buy|
|2/2/2016||Mackie||Boost Price Target||Hold||C$1.90 -> C$2.30|
|2/2/2016||Dundee Securities||Boost Price Target||Buy||C$3.50 -> C$3.60|
Earnings History for Merus Labs International (TSE:MSL)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Merus Labs International (TSE:MSL)
2017 EPS Consensus Estimate: ($0.03)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Merus Labs International (TSE:MSL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Merus Labs International (TSE MSL)
Insider Trades by Quarter for Merus Labs International (TSE MSL)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
Headline Trends for Merus Labs International (TSE:MSL)
Latest Headlines for Merus Labs International (TSE MSL)
Financials are not available for this stock.
Merus Labs International (TSE MSL) Chart for Saturday, November, 18, 2017